Skip to main content

Table 3 Parameters for the volumes and OARs

From: Dose-escalation by hypofractionated simultaneous integrated boost IMRT in unresectable stage III non-small-cell lung cancer

Dose Level

1

2

3

4

GTV(cm2)

51.0(45.4–309.1)

88.4(82.1–123.7)

73.81(41.22–106.79)

104.5(32.2–258.6)

PTV-G(cm2)

260.5(202.76–672.0)

298.7(242.5–374.0)

259.9(172.3–264.28)

324.2(159.6–663.3)

CTV(cm2)

138.7(114.3–568.7)

200.2(172.7–270.3)

198.1(105.6–292.2)

231.8(99.3–498.7)

PTV-C(cm2)

443.6(354.9–1020.6)

473.9(410.5–608.0)

386.1(288.6–623.9)

552.5(249.7–921.8)

Normal Lung

 V20 (%)

20.9(18.9–23.3)

18.9(16.7–23.2)

14.2(12.4–25.0)

22.24(16.9–28.4)

 MLD (Gy)

12.2(10.4–13.0)

9.8(9.4–11.7)

8.23(6.5–12.7)

12.6(8.3–17.8)

 V5%

44.54(34.9–57.5)

35.5(32.2–48.2)

37.8(23.9–51.7)

39.8(23.4–54.3)

 V5%(ipsilateral)

23.0(10.1–30.9)

25.1(23.16–35.6)

24.7(16.56–38.7)

24.3(16.3–31.8)

 V5%(contralateral)

59.7(58.3–60.2)

58.3(45.0–68.7)

61.48(52.063.54)

57.3(34.5–66.2)

Heart

 MHD (Gy)

12.49 (12.1–29.2)

13.3 (2.9–19.3)

12.1(4.9–16.9)

11.4 (6.0–27.0)

Spinal cord

 Dmax (Gy)

45.0 (39.7–48.0)

46.4 (31.5–48.9)

45.6(30.0–50.6)

43.9(4.9–47.7)

Esophagus

 Mean Dose (Gy)

28.8(15.2–37.0)

21.9 (10.1–50.0)

22.5(7.6–27.6)

24.0(4.9–39.4)

  1. Data were collected as the median and rang